ICYMI: 340B Program Raises Eyebrows in North Carolina

An inquiry by Senator Chuck Grassley led to the discovery that three NC nonprofit hospitals have made millions from the program, which was created to help the vulnerable or uninsured patients afford their medicines.

Allyson Funk
Allyson FunkApril 28, 2015

ICYMI: 340B Program Raises Eyebrows in North Carolina

340BSpotlight_HeaderIn case you missed it, a recent article in The Charlotte Observer spotlights new revelations about the 340B drug discount program in North Carolina. An inquiry by Senator Chuck Grassley (R-Iowa) in September 2014 led to the discovery that three North Carolina nonprofit hospitals—Duke University Hospital, Carolinas Medical Center and University of North Carolina (UNC) Hospitals—have made millions from the program, which was created to help the vulnerable or uninsured patients afford their medicines.

The following findings are raising eyebrows as to whether the program is functioning as intended:

  • Last year, Duke University Hospital purchased $65.8 million in medicines through 340B. The steep 340B discounts allowed the hospital to generate an additional $48.3 million in profit from sales of the medicines to patients. Duke’s profit from 340B is significantly more than the free or discounted care the hospital provides to low-income patients, which totaled just $35.2 million.
  • UNC reported receiving $65.4 million in revenue from medicines bought through the program from 2008 to 2011, but has not provided profit figures.

340BSpotlight_ThumbnailThe article mentions a letter Senator Grassley wrote last week to the administrator of the Health Resources and Services Administration (HRSA), the federal agency overseeing the program, and is awaiting a response. He says in the letter, “These numbers paint a very stark picture of how hospitals are reaping sizeable 340B discounts on drugs and then turning around and up-selling them to fully insured patients in order to maximize their spread.”

To learn more about 340B follow our 340B Spotlight blog posts or sign-up for personalized email updates.

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.